On June 22, Insilico Medicine fell 5.06% in regular trading, trading at HK$36.5/share, with turnover of HK$125 million.

On the news front, despite the company being formally included in the FTSE Global Equity Index Series on the same day, approximately 453 million restricted shares held by cornerstone investors and employees will see their lock-up period expire on June 29. These shares represent 81.25% of total outstanding shares, with an unlocked value of approximately HK$24.1 billion. Market concerns over potential concentrated selling pressure continue to weigh heavily on the stock.

On the fundamentals side, the company reported revenue declining 34.48% year-over-year, with a net loss attributable to shareholders of US$352 million. No earnings inflection point has materialized. The passive fund inflows expected from index inclusion appear insufficient to offset the overhang from the imminent lock-up expiry.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)